Kholidah
On October 6, 2026, the prominent South Korean rapper and entertainer Swings, born Moon Ji-hoon, provided a candid account of his recent health journey involving the administration of Mounjaro (tirzepatide), a medication primarily indicated for the treatment of type 2 diabetes and chronic weight management. The rapper, known for his long-standing presence in the Korean hip-hop industry and his recent pivot into cinema, shared a detailed anecdote regarding the physiological side effects he encountered after failing to adhere to clinical dietary recommendations provided by his medical practitioners.
The incident highlights the growing prevalence of GLP-1 receptor agonists in the public eye and underscores the significant risks associated with medical non-compliance when using potent pharmaceuticals for weight regulation.
A Chronology of the Incident and Medical Context
According to the statement released by Swings, the event took place during a medical consultation aimed at managing his body mass. The practitioner had reportedly administered a 12.5mg dose of Mounjaro, a dosage categorized as being on the higher end of the titration schedule for this specific medication. During the consultation, medical staff issued a explicit warning to the artist: the drug’s mechanism of action—which includes delayed gastric emptying—meant that consuming large quantities of food could lead to severe gastrointestinal distress, most notably vomiting.
Swings admitted that he initially dismissed the clinical advice, viewing the warning as an exaggeration of the drug’s potency. "Just now at the hospital, they warned me while giving treatment that I might vomit from the medication and told me to eat a little, but I thought that was ridiculous and ate a lot," he stated. Shortly thereafter, he engaged in a consumption pattern that defied the prescribed protocols, resulting in the adverse reaction he had been cautioned against. He later confirmed that his post-medication meal consisted of ten hamburgers, an intake that triggered the expected, yet severe, physical rejection of the food.
This incident is not an isolated event in Swings’ recent efforts to manage his weight. He has previously been transparent about his utilization of pharmacological aids in his dieting regimen. In the weeks preceding this event, he disclosed that he had successfully lost 6kg over a two-week period. However, he noted that the efficacy of the initial dosage seemed to plateau, leading him to seek further medical intervention and an increase in his prescribed dosage to the current 12.5mg level.
Understanding Mounjaro and GLP-1 Receptor Agonists
To understand the severity of the reaction described by Swings, it is necessary to examine the pharmacology of Mounjaro. Mounjaro is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These receptors play a critical role in metabolic homeostasis.
By mimicking these hormones, the medication regulates blood sugar levels and suppresses appetite. One of its primary side effects is gastroparesis, or delayed stomach emptying. When an individual takes a high dose of this medication, the rate at which food moves from the stomach to the small intestine is significantly slowed. If a patient consumes a high volume of food—particularly food high in fat or volume—the stomach remains distended for a prolonged period, leading to symptoms such as nausea, bloating, and vomiting.
Medical experts generally advise that patients on such medications adhere to a diet rich in protein and fiber while avoiding high-calorie, high-fat meals. The consumption of ten hamburgers, as reported by the artist, represents a caloric and volume intake that directly counteracts the physiological effects intended by the drug, creating a mechanical obstruction of the digestive process that inevitably leads to the symptoms experienced by the rapper.
Broader Implications and Public Health Discourse
The public disclosure by a high-profile figure like Swings brings necessary attention to the risks of self-management and non-compliance with medical advice concerning weight-loss medications. While GLP-1 agonists have been hailed as a breakthrough in treating obesity—a condition that affects millions worldwide and is linked to chronic illnesses such as cardiovascular disease and metabolic syndrome—their misuse remains a significant public health concern.
The cultural obsession with rapid weight loss, particularly within the entertainment industry, often pressures individuals to seek pharmaceutical shortcuts. When these drugs are utilized without a comprehensive understanding of their biological impact, or when warnings from licensed medical professionals are ignored, the risk of serious health complications increases.
Furthermore, the surge in demand for medications like Mounjaro and Ozempic (semaglutide) has led to global shortages, often making these drugs difficult to obtain for patients who require them for the management of type 2 diabetes. The discourse surrounding Swings’ experience serves as a cautionary tale regarding the "lifestyle" use of prescription medication versus its intended medical purpose.
Professional Trajectory and Public Profile
Swings has been a foundational figure in the Korean hip-hop scene since his debut in 2008. Over nearly two decades, he has transitioned from an underground rapper to a prominent label executive and, more recently, an actor. His move into the film industry, exemplified by his role in the recently released film Tazza 4, which premiered on September 23, 2026, has expanded his reach to a broader demographic.
Given his status as a public figure, his health-related disclosures carry significant weight. By choosing to share his struggle with weight management and his subsequent medical complications, Swings has inadvertently initiated a broader conversation about body image, the pressures of fame, and the responsible use of medical technology. While the tone of his social media updates was informal and anecdotal, the underlying reality of his experience provides a clear insight into the complexities of modern weight management.
Clinical Recommendations and Safety Protocols
Healthcare providers emphasize that patients seeking to undergo weight management through pharmacotherapy must follow a multi-faceted approach. This includes:
- Strict Nutritional Adherence: Patients are required to follow a structured meal plan that accounts for the drug’s effect on gastric motility.
- Gradual Titration: Medication dosages should be increased slowly under strict medical supervision to allow the body to adjust to the drug’s effects.
- Professional Monitoring: Regular check-ins with endocrinologists or bariatric specialists are essential to monitor side effects and long-term health outcomes.
- Behavioral Modification: Medication should be viewed as a tool to facilitate lifestyle changes, not as a replacement for consistent diet and exercise habits.
The incident involving Swings serves as a reminder that even when under the care of a hospital, the efficacy and safety of medical treatment are highly dependent on the patient’s adherence to clinical guidelines. As the use of GLP-1 receptor agonists continues to rise globally, the medical community maintains that education and patient responsibility are the primary defenses against adverse events.
In conclusion, while the rapper’s account of his experience with Mounjaro was shared with a level of candor that caught the attention of his fanbase, it simultaneously acts as an important case study on the consequences of ignoring medical directives. The entertainment industry, and the public at large, would do well to view such stories as an opportunity to better understand the mechanisms and limitations of modern obesity treatments, rather than as a mere tabloid curiosity. The focus, ultimately, must remain on the health and long-term well-being of the individual, prioritizing medical safety over the desire for rapid physical transformation.
